Climb Bio Inc. Common Stock (CLYM)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Climb Bio as a pre-revenue clinical-stage biotech, not a business with durable earnings. In fiscal 2023, the year ended 2023-12-31, it reported a net loss of $35.1M and diluted EPS of $-1.30. In fiscal 2024, the year ended 2024-12-31, the net loss was $73.9M, or $-1.53 per diluted share. In fiscal 2025, the year ended 2025-12-31, the net loss was $59.9M, or $-0.88 per diluted share. More recently, fiscal Q2 2026, the quarter ended 2026-06-30, showed a net loss of $13.5M and diluted EPS of $-0.18, while fiscal Q2 2025, the quarter ended 2025-06-30, had a net loss of $8.7M and EPS of $-0.13, so the loss widened. There is no revenue in the filed figures. Trailing free cash flow is $-53.1M, a -9.0% FCF yield on the $592.2M market cap. At the 2026-10-13 close of $10.31, FairStock's P/E is -12.57, P/B is 2.47, ROE -27.10%, ROCE -18.45%, and its score is 26/100. The Piotroski F-Score is 1/9—weak. The Altman Z-Score of 51.74 and D/E of 0.01 suggest low leverage, but that does not create an economic moat. The moat, if any, would come from patents, trial data, and regulatory exclusivity, none of which I can verify from these figures. The computed Lynch category is none, because it lost money in each of the last four years. The company is a lottery-like option on budoprutug in phase 2 and phase 1b, not a Graham bargain. I would demand proof of safety, efficacy, and a credible path to cash flow before treating the $592.2M market value as supported by business value.

In plain English: Climb Bio is a small healthcare company with 28 workers trying to develop a new antibody medicine for unable-to-be-treated immune diseases. It has no product sales and has been losing money, with the losses getting large. At the recent price of $10.31, the stock looks expensive against today's numbers because there are no profits or positive cash flow, though the price may reflect hope about future trials.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer